Navigation Links
Vasogen Announces 2008 Year-End Results
Date:2/27/2009

property has not been used to date in the Celacade System; however, we have retained rights to this technology for any potential use as it relates to its Celacade System.

Certain statements in this document constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, plans to consider a sale, merger, acquisition, or other alternatives resulting from our strategic review, statements regarding the status of development, or expenditures relating to the Celacade(TM) System or our VP series of drugs including VP015 and VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements. You should not place undue reliance on our forward-looking statements, which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the outcome of our strategic review, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors, including the current status of our programs, on capital availability, the potential dilutive effects of any financing and other risks detailed from time to t
'/>"/>

SOURCE Vasogen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vasogen Announces Sale of Patent Application and Provides Corporate Update
2. Vasogen Complies with NASDAQ Marketplace Rule 4350(c)(1)
3. Vasogen Provides Corporate Update
4. Vasogen Announces Third Quarter 2008 Results
5. Vasogen Announces Second Quarter 2008 Results
6. Vasogen Provides Corporate Update
7. Vasogen to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Vasogen Receives NASDAQ Notification Related to Minimum Bid Price
9. Vasogen Announces Implementation of Strategic Restructuring Plan
10. Vasogen Announces First Quarter 2008 Results
11. Vasogen to Webcast its Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic company ... has received a $1.5M Phase II SBIR grant ... further develop its therapeutic agent to reduce arteriovenous ... in end stage renal disease (ESRD) patients undergoing ... Institute of Diabetes and Digestive and Kidney Diseases ...
(Date:8/26/2015)... and BEIJING , August 26, 2015 ... Scene with Impressive Acheivements  DiaCardio wins 1 st ... The competition, led in Israel ... featured 21 startups from countries including the US, China ... and Latin America .  Impressive ...
(Date:8/26/2015)... OXFORD, England , August 26, 2015 ... P2i Ltd against Europlasma NV relating to P2i ... parties have resolved their dispute in the United ... or liability on the part of either party. As a ... the Central District of California dismissed ...
(Date:8/26/2015)... Bruno, CA. (PRWEB) , ... August 26, 2015 , ... ... major conferences to develop new business relationships with local sponsors in southern California. The ... to facilitate their drug development processes and regulatory pathways., , ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6P2i Settles United States Litigation 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... - Dr. Brad Thompson, President,and CEO of Oncolytics ... a,corporate overview of the company at Toronto CFA ... being held at the National Club, 303 Bay,Street, ... Inc. Oncolytics is a Calgary-based biotechnology company ...
... Nov. 15 Imaging,Diagnostic Systems, Inc., (OTC Bulletin Board: ... announced that its CT Laser,Mammography (CTLM(R)) system, designed as ... its future clinical applications were featured in,a cover story ... magazine. This,major article was contributed by Eric Milne, MD, ...
... Nov. 14 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... the,discovery, development and commercialization of novel drugs in ... today,announced its financial results for the third quarter ... The net loss for the three months ...
Cached Biology Technology:Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society 2New Optical Breast Cancer Imaging Technology Garners Cover Story in National Radiology Magazine 2New Optical Breast Cancer Imaging Technology Garners Cover Story in National Radiology Magazine 3Advanced Life Sciences Announces Third Quarter 2007 Financial Results 2Advanced Life Sciences Announces Third Quarter 2007 Financial Results 3Advanced Life Sciences Announces Third Quarter 2007 Financial Results 4Advanced Life Sciences Announces Third Quarter 2007 Financial Results 5Advanced Life Sciences Announces Third Quarter 2007 Financial Results 6Advanced Life Sciences Announces Third Quarter 2007 Financial Results 7Advanced Life Sciences Announces Third Quarter 2007 Financial Results 8Advanced Life Sciences Announces Third Quarter 2007 Financial Results 9
(Date:8/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Card Alliance and the EMV Migration Forum.  ... Card Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. ... leaders promoting adoption of smart card technology. ...
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/10/2015)... and TELTOW, Germany , August 10, ... (SMI), a world leader in Eye Tracking Technology for ... its OEM Eye Tracking Platform for integration into all ... contains reference designs for seamless integration of eye tracking ... reality HMDs and augmented reality smart glasses. Omnivision,s leading ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... LA JOLLA, CAThe seeds sprouting in your spring garden may still ... a finite energy pack contained within each seed. Once those resources ... on a "green" photosynthetic program. Researchers at the Salk Institute for ... relayed. In a study published in the May 24, 2011, ...
... 18, 2011 The Initiative for a Competitive Inner City ... 100 list of the fastest-growing inner city companies in the ... year,s list.  The Inner City 100 program recognizes successful inner ... innovative business practices and job creation in America,s urban communities. ...
... A nationwide network to monitor and maintain honeybee health ... five-year, $5 million program funded by the U.S. Department ... led by Penn State. The Bee Informed Partnership ... management practices and use them to develop best practices ...
Cached Biology News:It's not easy being green 2It's not easy being green 3Prometheus Research Ranked #3 in 13th Annual ICIC and Fortune Magazine's Inner City 100 2Prometheus Research Ranked #3 in 13th Annual ICIC and Fortune Magazine's Inner City 100 3Penn State leads in honey bee health initiative 2
... save space and organize gloves, ... other garb. They are the ... small parts used in labs, ... Many other sizes and custom ...
... Quixell, manufactured by Stoelting, selects single ... control. In no time at all, a ... on the keypad...the cell is collected into ... individual wells of a microtiter plate. Quixells ...
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known fish microRNAs ...
... for genome-wide microRNA expression profiling and ... Paraflo microfluidic on-chip synthesis platform. These ... our comprehensive microRNA Expression Profiling Service. ... Maize microRNA Microarray contains all known ...
Biology Products: